PDSB - PDS Biotech reaches an enrollment target for mid-stage cancer trial for lead asset

Clinical-stage immunotherapy company, PDS Biotechnology (NASDAQ:PDSB), announced on Tuesday the achievement of a key enrollment target in Phase 2 clinical trial for a combination therapy involving its lead candidate PDS0101 in advanced HPV-associated cancers. The 56-patient trial led by National Cancer Institute (NCI) is designed to assess PDS0101 (Versamune+HPV16mix) in combination with two experimental immune-modulating agents. The company said that the NCI has now reached the full enrollment of 30 patients in the checkpoint inhibitor (CPI) refractory arm of the trial. With 45 patients recruited to date, the study will continue to add refractory and CPI naïve patients until the full enrollment target is met, PDS Biotechnology (PDSB) said. Read more on a recent interim data readout from the study.

For further details see:

PDS Biotech reaches an enrollment target for mid-stage cancer trial for lead asset